FIL Ltd Purchases 198,412 Shares of Insmed Incorporated (NASDAQ:INSM)

FIL Ltd increased its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 8.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,638,160 shares of the biopharmaceutical company's stock after acquiring an additional 198,412 shares during the quarter. FIL Ltd owned about 1.47% of Insmed worth $182,139,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the period. Geode Capital Management LLC grew its stake in Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after buying an additional 273,759 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in Insmed by 8.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock valued at $215,842,000 after acquiring an additional 242,242 shares during the period. William Blair Investment Management LLC lifted its position in Insmed by 0.5% during the fourth quarter. William Blair Investment Management LLC now owns 2,433,443 shares of the biopharmaceutical company's stock worth $168,005,000 after acquiring an additional 12,535 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of Insmed by 5.2% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,959,718 shares of the biopharmaceutical company's stock worth $135,299,000 after acquiring an additional 96,377 shares during the period.

Remove Ads

Insmed Price Performance

INSM stock traded up $1.60 during midday trading on Monday, reaching $70.17. 389,733 shares of the stock were exchanged, compared to its average volume of 2,268,166. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a fifty day moving average price of $76.20 and a 200 day moving average price of $73.65. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $12.76 billion, a PE ratio of -12.55 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. As a group, analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 1,384 shares of the company's stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total value of $95,108.48. Following the sale, the insider now owns 100,165 shares in the company, valued at approximately $6,883,338.80. The trade was a 1.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the transaction, the chief executive officer now owns 334,186 shares of the company's stock, valued at $25,742,347.58. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 499,613 shares of company stock valued at $39,569,355. Insiders own 4.60% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on INSM. Truist Financial increased their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Finally, Guggenheim restated a "buy" rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and an average price target of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.